Methods |
Randomized
Multicentre |
Participants |
Adults (mean 60)
Severe bronchopulmonary infections
Hospitalized |
Interventions |
Atypical: PO pefloxacin 400 mg X 2/d
Non‐atypical: IV ceftazidime 2 G X 2/d |
Outcomes |
Success not defined in study
Bacteriological outcome |
Notes |
Severe infection = failure on previous treatment, multi‐resistant pathogens, severe underlying disease, poor general condition |
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
Random sequence generation (selection bias) |
Unclear risk |
Not identified |
Allocation concealment (selection bias) |
Unclear risk |
Not identified |
Incomplete outcome data (attrition bias)
Mortality |
Low risk |
All patients evaluated |
Incomplete outcome data (attrition bias)
Failure |
High risk |
156/170 patients evaluated |
Selective reporting (reporting bias) |
Low risk |
Not identified |
Other bias |
Unclear risk |
Unknown sponsorship |
Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
None |
Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
None |